Cell Growth & Differentiation, Vol 8, Issue 8 871-879, Copyright © 1997 by American Association of Cancer Research

ARTICLES

Treatment of U937 cells with bufalin induces the translocation of casein kinase 2 and modulates the activity of topoisomerase II prior to the induction of apoptosis

M Watabe, S Nakajo, T Yoshida, Y Kuroiwa and K Nakaya
Laboratory of Biological Chemistry, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan.

The treatment of human leukemia U937 cells with 10(-8) M bufalin in the absence of serum resulted in the immediate translocation of casein kinase 2 (CK 2) from the cytoplasm to the nucleus, as determined by confocal laser-scanning microscopy. Concomitantly, the activity of topoisomerase (topo) II, as determined by monitoring activities specific to this enzyme such as DNA relaxation, DNA decatenation, and topo II-mediated DNA cleavage, was enhanced. The activity reached a maximum after 3 h and then decreased markedly after treatment with bufalin for 9 h. The amount of a complex of CK 2 and topo IIalpha in U937 cells was estimated by immunoprecipitation with antibodies raised against subunits of CK 2 and against topo IIalpha. The amount increased just after the start of treatment with bufalin and reached a maximum at 6 h. The results suggest that the topo IIalpha in the complex might have been phosphorylated by the translocated CK 2 and that the topo activity was stimulated by such phosphorylation. Apoptotic U937 cells with fragmented nuclei were observed between 9 and 12 h after the start of treatment using 10(-8) M bufalin. Therefore, it appears that the bufalin signal was transmitted to the nucleus by the translocation of CK 2, which formed a complex with topo IIalpha and modulated the activity of this enzyme, leading to the induction of apoptosis.

This article has been cited by other articles:

				M. Watabe and T. Nakaki Mitochondrial Complex I Inhibitor Rotenone Inhibits and Redistributes Vesicular Monoamine Transporter 2 via Nitration in Human Dopaminergic SH-SY5Y Cells Mol. Pharmacol., October 1, 2008; 74(4): 933 - 940. [Abstract] [Full Text] [PDF]

				R. A. Newman, P. Yang, A. D. Pawlus, and K. I. Block Cardiac Glycosides as Novel Cancer Therapeutic Agents Mol. Interv., February 1, 2008; 8(1): 36 - 49. [Abstract] [Full Text] [PDF]

				M. Watabe and T. Nakaki Mitochondrial Complex I Inhibitor Rotenone-Elicited Dopamine Redistribution from Vesicles to Cytosol in Human Dopaminergic SH-SY5Y Cells J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 499 - 507. [Abstract] [Full Text] [PDF]

				M. Watabe and T. Nakaki Rotenone Induces Apoptosis via Activation of Bad in Human Dopaminergic SH-SY5Y Cells J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 948 - 953. [Abstract] [Full Text] [PDF]

				M. Watabe, K. Hishikawa, A. Takayanagi, N. Shimizu, and T. Nakaki Caffeic Acid Phenethyl Ester Induces Apoptosis by Inhibition of NF{kappa}B and Activation of Fas in Human Breast Cancer MCF-7 Cells J. Biol. Chem., February 13, 2004; 279(7): 6017 - 6026. [Abstract] [Full Text] [PDF]

				M. Watabe, K. Machida, and H. Osada MT-21 Is a Synthetic Apoptosis Inducer That Directly Induces Cytochrome c Release from Mitochondria Cancer Res., September 1, 2000; 60(18): 5214 - 5222. [Abstract] [Full Text]

				S. Schoonbroodt, V. Ferreira, M. Best-Belpomme, J. R. Boelaert, S. Legrand-Poels, M. Korner, and J. Piette Crucial Role of the Amino-Terminal Tyrosine Residue 42 and the Carboxyl-Terminal PEST Domain of I{kappa}B{alpha} in NF-{kappa}B Activation by an Oxidative Stress J. Immunol., April 15, 2000; 164(8): 4292 - 4300. [Abstract] [Full Text] [PDF]

				C. Guo, S. Yu, A. T. Davis, H. Wang, J. E. Green, and K. Ahmed A Potential Role of Nuclear Matrix-associated Protein Kinase CK2 in Protection against Drug-induced Apoptosis in Cancer Cells J. Biol. Chem., February 16, 2001; 276(8): 5992 - 5999. [Abstract] [Full Text] [PDF]